IPTACOPAN ASH UPDATE
Significant experience in non-malignant hematology and rare
disease provides strong foundation for launch
Track record of
execution in rare
hematology /
oncology conditions
→ Promacta market leadership in SAA (ultra-rare) and ITP (rare) based on
deep understanding of HCP insights and patient needs / motivations;
also an oral option in originally infusion-driven market
→ Building on rare disease playbook from Vijoice and Afinitor TSC launches,
including early and critical focus on patient engagement and advocacy
Existing
→
~2.5k hematologists / oncologists seeing PNH patients
relationships with
→
PNH treaters
Rare disease, but treated and managed not just by experts in large centers,
but also community HCPs
28
IPTACOPAN ASH UPDATE | DECEMBER 13, 2022
→ Strong existing customer relationships with majority of PNH treaters
→ Top medical experts engaged in either clinical studies or advisory capacity
→ Account profiling underway to identify individual success levers
NOVARTIS | Reimagining MedicineView entire presentation